Corvus Pharmaceuticals to Present Soquelitinib Data at SID Annual Meeting
Event summary
- Corvus Pharmaceuticals will host an investor and analyst meeting on May 14, 2026, to highlight soquelitinib data presented at the SID Annual Meeting.
- Two oral presentations, including a late-breaker, will cover Phase 1 clinical trial data for soquelitinib in atopic dermatitis.
- The meeting will feature guest speakers Albert S. Chiou, M.D., MBA, and Kavita Sarin, M.D., Ph.D., from Stanford University.
- First quarter 2026 financial results will be reported on May 7, 2026, without a conference call due to the upcoming investor meeting.
The big picture
Corvus Pharmaceuticals is positioning soquelitinib as a novel ITK inhibitor with potential for drug-free remissions in atopic dermatitis. The upcoming data presentations and investor meeting are critical for validating the drug's mechanism of action and supporting its development pipeline. The biopharmaceutical company is leveraging academic partnerships to bolster its clinical trial data and strategic narrative.
What we're watching
- Clinical Efficacy
- How the immunologic and biomarker data supporting drug-free remissions will impact the perception of soquelitinib's potential.
- Regulatory Pathway
- Whether the Phase 1 data will accelerate the development timeline for soquelitinib in atopic dermatitis.
- Market Positioning
- The pace at which Corvus can differentiate soquelitinib in the competitive landscape of atopic dermatitis treatments.
Related topics